Skip to main content
Erschienen in: Diabetologia 2/2014

01.02.2014 | Short Communication

Are we overestimating the loss of beta cells in type 2 diabetes?

verfasst von: Lorella Marselli, Mara Suleiman, Matilde Masini, Daniela Campani, Marco Bugliani, Farooq Syed, Luisa Martino, Daniele Focosi, Fabrizio Scatena, Francesco Olimpico, Franco Filipponi, Pellegrino Masiello, Ugo Boggi, Piero Marchetti

Erschienen in: Diabetologia | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Previous work has demonstrated that beta cell amount (whether measured as beta cell mass, beta cell volume or insulin-positive area) is decreased in type 2 diabetes; however, recent findings suggest that mechanisms other than death may contribute to beta cell failure in this disease. To better characterise beta cell mass and function in type 2 diabetes, we performed morphological, ultra-structural and functional studies using histological samples and isolated islets.

Methods

Pancreases from ten non-diabetic (ND) and ten matched type 2 diabetic organ donors were studied by insulin, glucagon and chromogranin A immunocytochemistry and electron microscopy (EM). Glucose-stimulated insulin secretion was assessed using isolated islets and studies were performed using independent ND islet preparations after 24 h exposure to 22.2 mmol/l glucose.

Results

Immunocytochemistry showed that the fractional islet insulin-positive area was lower in type 2 diabetic islets (54.9 ± 6.3% vs 72.1 ± 8.7%, p < 0.01), whereas glucagon (23.3 ± 5.4% vs 20.2 ± 5.3%) and chromogranin A (86.4 ± 6.1% vs 89.0 ± 5.5%) staining was similar between the two groups. EM showed that the proportion of beta cells in type 2 diabetic islets was only marginally decreased; marked beta cell degranulation was found in diabetic beta cells; these findings were all reproduced after exposing isolated ND islets to high glucose. Glucose-stimulated insulin secretion was 40–50% lower from type 2 diabetic islets (p < 0.01), which again was mimicked by culturing non-diabetic islets in high glucose.

Conclusions/interpretation

These results suggest that, at least in subgroups of type 2 diabetic patients, the loss of beta cells as assessed so far might be overestimated, possibly due to changes in beta cell phenotype other than death, also contributing to beta cell failure in type 2 diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef
2.
Zurück zum Zitat Meier JJ (2008) Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 51:703–713PubMedCrossRef Meier JJ (2008) Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 51:703–713PubMedCrossRef
3.
Zurück zum Zitat Ahrén B (2005) Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 5:275–286PubMedCrossRef Ahrén B (2005) Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 5:275–286PubMedCrossRef
4.
Zurück zum Zitat Hanley NA, Hanley KP, Miettinen PJ, Otonkoski T (2008) Weighing up beta-cell mass in mice and humans: self-renewal, progenitors or stem cells? Mol Cell Endocrinol 288:79–85PubMedCrossRef Hanley NA, Hanley KP, Miettinen PJ, Otonkoski T (2008) Weighing up beta-cell mass in mice and humans: self-renewal, progenitors or stem cells? Mol Cell Endocrinol 288:79–85PubMedCrossRef
5.
Zurück zum Zitat Donath MY, Halban PA (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581–589PubMedCrossRef Donath MY, Halban PA (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581–589PubMedCrossRef
6.
Zurück zum Zitat Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
7.
Zurück zum Zitat Marchetti P, Lupi R, del Guerra S et al (2009) Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 32(Suppl 2):S178–S183PubMedCrossRef Marchetti P, Lupi R, del Guerra S et al (2009) Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 32(Suppl 2):S178–S183PubMedCrossRef
8.
9.
Zurück zum Zitat Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150:1223–1234PubMedCentralPubMedCrossRef Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150:1223–1234PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Meier JJ, Breuer TG, Bonadonna RC et al (2012) Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 55:1346–1354PubMedCrossRef Meier JJ, Breuer TG, Bonadonna RC et al (2012) Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 55:1346–1354PubMedCrossRef
11.
Zurück zum Zitat Tancredi M, Marselli L, Lencioni C et al (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: a case report. Islets 3:231–233PubMedCrossRef Tancredi M, Marselli L, Lencioni C et al (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: a case report. Islets 3:231–233PubMedCrossRef
12.
Zurück zum Zitat Marchetti P, Bugliani M, Lupi R et al (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50:2486–2494PubMedCrossRef Marchetti P, Bugliani M, Lupi R et al (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50:2486–2494PubMedCrossRef
13.
Zurück zum Zitat Marselli L, Thorne J, Dahiya S et al (2010) Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One 5:e11499PubMedCentralPubMedCrossRef Marselli L, Thorne J, Dahiya S et al (2010) Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One 5:e11499PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Kilimnik G, Zhao B, Jo J et al (2011) Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes. PLoS One 6:e27445PubMedCentralPubMedCrossRef Kilimnik G, Zhao B, Jo J et al (2011) Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes. PLoS One 6:e27445PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diab Obes Metab 10(Suppl 4):32–34CrossRef Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diab Obes Metab 10(Suppl 4):32–34CrossRef
16.
Zurück zum Zitat Hanley AC, Austin E, Assouline-Thomas B et al (2010) Beta cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 151:1462–1472PubMedCrossRef Hanley AC, Austin E, Assouline-Thomas B et al (2010) Beta cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 151:1462–1472PubMedCrossRef
17.
Zurück zum Zitat Deng S, Vatamaniuk M, Huang X et al (2004) Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624–632PubMedCrossRef Deng S, Vatamaniuk M, Huang X et al (2004) Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624–632PubMedCrossRef
Metadaten
Titel
Are we overestimating the loss of beta cells in type 2 diabetes?
verfasst von
Lorella Marselli
Mara Suleiman
Matilde Masini
Daniela Campani
Marco Bugliani
Farooq Syed
Luisa Martino
Daniele Focosi
Fabrizio Scatena
Francesco Olimpico
Franco Filipponi
Pellegrino Masiello
Ugo Boggi
Piero Marchetti
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 2/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-3098-3

Weitere Artikel der Ausgabe 2/2014

Diabetologia 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.